Gilead Sciences was recently ordered to pay $2.54 billion to Merck to resolve a long-running patent dispute concerning its blockbuster patent sellers Sovaldi (earning Gilead $19 billion) and Harvoni (earning Gilead $23 billion) for hepatitis C treatment.

The patent dispute originated with smaller companies that are now owned by two of the world’s largest drug makers.